Medgenics Announces Beta Thalassemia Research Program

Medgenics, Inc. (NYSE MKT:MDGN), today announced the initiation of a research program to evaluate the use of TARGTEPOTM alone or in
combination with iron restriction to ameliorate erythropoiesis in Beta Thalassemia Intermedia (non-transfusion dependent thalassemia or NTDT) and Beta Thalassemia Major (transfusion dependent thalassemia or TDT). Dr. Stefano Rivella, Professor of Pediatrics and Ohene-Frempong Chair on Sickle Cell Anemia at The Children’s Hospital of Philadelphia, will lead the research program.

This entry was posted in Recent Development News: Q4 - 2015, Recent Developments. Bookmark the permalink.
Read Full Article »